Introduction
============

The prevalence of type 2 diabetes (T2D) is dramatically increasing worldwide. T2D is characterized by low-grade inflammation, insulin resistance, and pancreatic β-cell failure. Recently, increasing evidence has addressed the link between T2D and gut microbiota. The underlying mechanism of T2D is also of interest. In addition to genetic, physiological and environmental factors, gut microbiota also markedly contribute to the incidence of T2D ([@ref-4]; [@ref-53]). T2D patients have a moderate degree of gut microbial dysbiosis ([@ref-46]). Germ-free mice exhibit reduced susceptibility to high-fat diet-induced obesity, insulin resistance, and glucose intolerance ([@ref-47]). Moreover, transplantation of gut microbiota from ob/ob mice to germ-free mice leads to obesity and insulin resistance ([@ref-54]). These studies suggest that changes in gut microbiota may be potential targets for the treatment of T2D.

As a prebiotic, inulin (extracted from chicory root), cannot be hydrolyzed by human small intestinal digestive enzymes but is fermented by certain bacteria, such as *Bifidobacterium* and *Lactobacillus*, in the large intestine with lactate and short-chain fatty acids (SCFAs) ([@ref-2]). Inulin oligofructose (OFS, a chicory inulin-type fructan with a low degree of polymerization) has been shown to reduce blood glucose and moderate insulin resistance in diabetic rats and mice ([@ref-8]; [@ref-11]; [@ref-13]). In healthy humans, OFS promotes satiety after meals ([@ref-11]; [@ref-12]). The useful effects of inulin are primarily related to an increase in glucagon-like peptide-1 (GLP-1) ([@ref-14]). GLP-1 is released from intestinal L cells upon stimulation by nutrients. GLP-1 promotes insulin secretion and pancreas β-cell proliferation, controls glycogen synthesis in muscle cells, and enhances satiety ([@ref-39]).

However, the effect of inulin on the gut microbiome in diabetic rats is still not clear. Recently, 16S rRNA gene sequencing in gut microbiota was utilized to simultaneously assess hundreds of gut bacteria. By utilizing 16s rRNA gene sequencing, we identified the changes that occur in the gut microbiota of inulin-treated diabetic rats. We hypothesized that inulin treatment would normalize gut microbiota in diabetic rats. The purpose of this research was to identify the beneficial bacteria in the gut microbiota that are responsible for the effects of inulin treatment.

Materials and Methods
=====================

Study design and animal experiments
-----------------------------------

All procedures were undertaken with the approval of the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 Feb 2015), and all efforts were made to minimize suffering. Five-week-old male Sprague-Dawley (SD) rats (158.3 ± 14.8 g) were obtained from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China, SCXK-2014-0013). All rats were maintained in cages at 24 ± 1 °C with lights on from 6:00 a.m. to 6:00 p.m. and were given free access to food and water.

Control rats were fed a standardized diet (kcal %: 10% fat, 20% protein, and 70% carbohydrate; 3.85 kcal/gm), and experimental rats were fed a high-fat diet (kcal %: 45% fat, 20% protein, and 35% carbohydrate; 4.73 kcal/gm; Research Diet, New Brunswick, NJ, USA) for four weeks and then intraperitoneally injected with streptozotocin (STZ, 30 mg/kg body weight) to induce diabetes ([@ref-17]). The diabetic animals were fed continuously on the high-fat diet throughout the remainder of the study. Fasting blood glucose (FBG) \>11.1 mmol/L was determined to be the standard concentration for the type 2 diabetes model. Diabetic rats were randomly divided into two groups: an inulin-treated diabetic group (DM + inulin, Vilof™ Soluble Dietary Fiber; BAHEAL Medical Inc., Qingdao, China and Fengning Ping'an High-tech Industrial Co., Ltd., Hebei, China, orally administered 3 g Vilof™ Soluble Dietary Fiber powder/kg body weight/day, *n* = 6) and an untreated-diabetic group (DM, orally administered the same volume of normal saline, *n* = 6). Vilof™ Soluble Dietary Fiber powder contains 91% inulin-type fructan and 9% sucrose, fructose, and glucose. Control rats were randomly divided into an untreated control group (CON, *n* = 6, administered normal saline) and an inulin-treated control group (CON + inulin, *n* = 6, administered 3 g Vilof™ Soluble Dietary Fiber powder/kg body weight/day). After 12 weeks, fresh stool samples were obtained by stimulating the anus and were immediately frozen and stored at −80 °C for subsequent analysis. After 12 h of food deprivation, the rats were anesthetized (ketamine 100 mg/kg i.p.; Pharmacia and Upjohn Ltd., Crawley, UK), and blood samples were collected from the intraorbital retrobulbar plexus at 8 a.m. ([@ref-17]). The rats were thensacrificed. Epididymal fat and liver was quickly collected and kept at −80 °C.

Measurements of body weight and fasting blood glucose (FBG)
-----------------------------------------------------------

Body weight and FBG were monitored monthly with Bayer Contour TS glucometer (Bayer, Hamburg, Germany).

Oral glucose tolerance test (OGTT) and area under the curve
-----------------------------------------------------------

After fasting for 12 h, an OGTT was performed. Glucose (2 g/kg body weight) was orally administered to the rats. Glucose levels in the blood obtained from the tail were recorded before and 30, 60, and 120 min after the glucose load. The area under the curve (AUC) was calculated by the linear trapezoid method ([@ref-63]).

Measurement of serum insulin, GLP-1, lipid profile, interleukin 6 (IL-6), and HOMA-IR
-------------------------------------------------------------------------------------

After 12 h of food deprivation, rat serum was obtained to analyze insulin (ELISA, Millipore, Billerica, MA, USA), GLP-1 (ELISA, Millipore, Billerica, MA, USA), total cholesterol (TC, enzyme end-point method; Roche Diagnostics, GmbH, Mannheim, Germany), triglyceride (TG, enzyme end-point method, Roche Diagnostics, GmbH, Mannheim, Germany), and IL-6 (ELISA, Millipore, Billerica, MA, USA) concentrations, according to the manufacturer's instruction. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by the following formula: fasting blood glucose (FBG, mmol/L) × fasting serum insulin (µIU/mL)/ 22.5.

Measurement of liver TG content
-------------------------------

Liver tissue (100 mg) was homogenized in 350 µL ethanolic KOH, then incubated overnight at 55 °C. The next day, 1,000 µL H2O: EtOH (1:1) was added to the tube. The samples were centrifuged for 5 min. The supernatant was used to measure the content of TG using a colorimetric kit (Biovision, Milpitas, CA, USA).

Quantitative PCR assay of *Il6* mRNA expression in adipose tissue, *G6pc* and *Pepck* mRNA expression in liver
--------------------------------------------------------------------------------------------------------------

Total RNA from epididymal fat and liver was extracted by using RNA Isolation Kit (RNeasy kit, Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA was reverse transcribed by Superscript II (Invitrogen, Carlsbad, CA, USA). Quantitative PCR was performed by using SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). The primer was produced by Applied Biosystems (Foster City, CA, USA). Specific primers for rat *Il6* mRNA were 5′-CTGGTCTTCTGGAGTTCCGT-3′ (forward) and 5′-TGGTCCTTAGCCACTCCTTCT-3′ (reverse), rat *Pepck* mRNA were 5′-CCAAGAGCAGAGAGACACCG-3′ (forward) and 5′-ATACATGGTGCGGCCTTTCA-3′ (reverse), rat *G6pc* mRNA were 5′-GCGTGCCATAGGACTCATCA-3′ (forward) and 5′-CACCAGCAAACAATTGCCCA-3′ (reverse). The products were run in the ABI Prism 7700 Sequence Detection system (Applied Biosystems, Foster City, CA, USA). The cycling conditions were set at 95 °C for 15 min, followed by 40 cycles of 95 °C for 15 s, 55 °C for 1 min and 72 °C for 1 min. *Gadph* was used for normalization. Relative quantification of mRNA was calculated using the comparative threshold cycle (Ct) method.

Fecal DNA extraction and amplification
--------------------------------------

Total DNA from fecal samples was isolated using a QIAmp DNA Stool Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The 16S rRNA hypervariable regions V3--V4 were PCR amplified using barcoded, gene specific primers 341F (5′-CCTAYGGGRBGCASCAG-3′) and 806R (5′-GGACTACNNGGGTATCTAAT-3′) with Phusion High-Fidelity PCR Master Mix (New England Biolabs, Ipswich, MA, USA) followed by library preparation (TruSeq DNA PCR-Free Sample Preparation Kit; Illumina, San Diego, CA, USA).

Pyrophosphate sequencing and primary data analysis
--------------------------------------------------

Pyrosequencing was performed on an Illumina HiSeq 2500 platform (San Diego, CA, USA), and 250-bp paired-end reads were generated. Paired-end reads were connected using FLASH (John Hopkins University School of Medicine, Baltimore, MD, USA) ([@ref-38]). Raw reads were filtered with a specific standard to gain high quality reads using QIIME version 1.7.0 ([@ref-15]). Sequences analysis was performed using UPARSE version 7.0.1001 ([@ref-19]). The operational taxonomic units (OTUs) were generated from ≥97% similarity sequences. Representative sequences for each OTU were screened for further annotation.

Taxon composition and species diversity analysis
------------------------------------------------

OTUs were annotated with taxonomic information based on the RDP classifier version 2.2 ([@ref-56]) algorithm using the Greengene database ([@ref-18]). OTU abundance data were normalized using a standard sequence number corresponding to the sample with least sequences. The relative proportion of each OTU was examined at the Phylum, Class, Order, Family, Genus and Species levels.

Alpha (within a community) and beta (between communities) diversity were analyzed with QIIME version 1.7.0. For alpha diversity, Chao1 and Shannon indices were calculated to identify community richness and diversity, respectively. For beta diversity, principal coordinates analysis (PCoA) plots were generated using both weighted (which considers the abundance of each species) and unweighted (which considers the presence or absence of each species) UniFrac ([@ref-36]). Unweighted pair-group method with arithmetic means (UPGMA) clustering was employed as the hierarchical clustering method to interpret the distance matrix using average linkage. In addition, linear discriminant analysis of the effect size (LEfSe) was performed to calculate OTU abundance and to determine the differences among groups ([@ref-51]). The threshold for the logarithmic linear discriminant analysis (LDA) score was \>3.0.

Data analysis
-------------

The data are expressed as the mean ± SD. When the data were normal and variances were equal, differences among the groups were analyzed using one-way ANOVA followed by Tukey's post hoc test. Otherwise, the Kruskal--Wallis test and the Mann--Whitney test were applied. Spearman's correlation analysis was performed to identify the correlations. A *P*-value ≤0.05 was considered statistically significant (Prism version 5.0 for Windows; GraphPad Software, San Diego, CA, USA).

Results
=======

Body weight
-----------

Diabetic rats exhibited significantly lower body weight (*P* \< 0.01, [Fig. 1A](#fig-1){ref-type="fig"}), while inulin-treated diabetic rats had an increased body weight compared with the control diabetic rats (*P* \< 0.01, [Fig. 1A](#fig-1){ref-type="fig"}).

![The effect of inulin on body weight, fasting blood glucose, blood glucose in OGTT, serum insulin, HOMA-IR index, GLP-1, blood lipid panels, pro-inflammation cytokine, and hepatic TG content.\
(A) Body weight, (B) fasting blood glucose, (C) blood glucose in oral glucose tolerance test, (D) area under curve (AUC) in OGTT, (E) serum insulin, (F) HOMA-IR, (G) GLP-1, (H) total cholesterol (TC), (I) triglyceride (TG), (J) interleukin 6 (IL-6), and (K) hepatic TG content. Data are presented as means ± SD (*n* = 6). Data was \**P* \< 0.05, \*\**P* \< 0.01, ^NS^ not significant (one-way ANOVA followed by Tukey's post hoc test).](peerj-06-4446-g001){#fig-1}

Fasting blood glucose level and glucose tolerance
-------------------------------------------------

Diabetic rats showed statistically elevated FBG levels compared to normal control rats (*P* \< 0.01, [Fig. 1B](#fig-1){ref-type="fig"}), and inulin treatment reduced FBG levels in diabetic rats (*P* \< 0.01, [Fig. 1B](#fig-1){ref-type="fig"}). According to the oral glucose tolerance test, blood glucose levels significantly increased before and after glucose load (*P* \< 0.01, [Fig. 1C](#fig-1){ref-type="fig"}) in diabetic rats. The elevated glucose area under the curve (AUC) on the OGTT (*P* \< 0.01) in diabetic rats indicated severe glucose intolerance in diabetic rats ([Fig. 1D](#fig-1){ref-type="fig"}). Inulin treatment significantly reduced blood glucose levels before and after glucose load (*P* \< 0.05 or *P* \< 0.01) in diabetic rats ([Fig. 1C](#fig-1){ref-type="fig"}). Similarly, diabetic rats treated with inulin treatment exhibited a reduced glucose AUC by 25.8% (*P* \< 0.01, [Fig. 1D](#fig-1){ref-type="fig"}).

Fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)
--------------------------------------------------------------------------------

Dramatic increases in serum insulin levels and HOMA-IR in diabetic rats were noted (*P* \< 0.01, [Figs. 1E](#fig-1){ref-type="fig"} and [1F](#fig-1){ref-type="fig"}). Inulin treatment reduced serum insulin levels and HOMA-IR in diabetic rats (*P* \< 0.01, [Figs. 1E](#fig-1){ref-type="fig"} and [1F](#fig-1){ref-type="fig"}).

Serum biochemical parameters
----------------------------

Fasting serum GLP-1 levels decreased in the diabetic group (*P* \< 0.01), while inulin treatment increased fasting serum GLP-1 levels (*P* \< 0.01, [Fig. 1G](#fig-1){ref-type="fig"}). Serum TC, TG, and IL-6 significantly increased in the DM group (*P* \< 0.01, [Figs. 1H](#fig-1){ref-type="fig"}--[1J](#fig-1){ref-type="fig"}). Inulin treatment reduced serum TC, TG and IL-6 levels in diabetic rats (*P* \< 0.05, [Figs. 1H](#fig-1){ref-type="fig"}--[1J](#fig-1){ref-type="fig"}).

Liver TG content
----------------

Liver TG content in diabetic rats significantly increased (*P* \< 0.01, [Fig. 1K](#fig-1){ref-type="fig"}). Inulin treatment reduced liver TG content slightly (*P* \> 0.05, [Fig. 1K](#fig-1){ref-type="fig"}).

Epididymal fat *Il6* expression and hepatic *Pepck* and *G6pc* expression
-------------------------------------------------------------------------

The expression of *Il6* in white adipose tissue and hepatic gluconeogenesis markers (*Pepck* and *G6pc*) expression increased significantly in diabetic rats (*P* \< 0.01, [Figs. 2A](#fig-2){ref-type="fig"}--[2C](#fig-2){ref-type="fig"}). Inulin treatment reduced epididymal fat *Il6* expression and hepatic *Pepck* and *G6pc* expression (*P* \< 0.01, [Figs. 2A](#fig-2){ref-type="fig"}--[2C](#fig-2){ref-type="fig"}).

![Pro-inflammatory cytokine and gluconeogenesis marker expression in white adipose tissue and liver.\
(A) *Il6* expression in epididymal fat, (B) *Pepck* expression in liver, and (C) *G6pc* expression in liver. \*\**P* \< 0.01, ^NS^ not significant (one-way ANOVA followed by Tukey's post hoc test).](peerj-06-4446-g002){#fig-2}

Characterization of gut microbiota
----------------------------------

To describe the composition of the gut microbiota, a total of 1,402,994 pyrosequencing reads (69,281 unique sequences) were obtained from 24 stool samples. The 16s sequence data generated in this study were submitted to the NCBI Sequence Read Archive (SRA) database (accession number [SRP095682](https://www.ncbi.nlm.nih.gov/sra?term=SRP095682)). Among them, 1,108,097 reads (48,153 sequences) were generated after quality filtering, with an average of 2,386 ± 1,699 sequences being recovered per sample. The high-quality sequences were then delineated into 873 operational taxonomic units (OTUs) at the similarity cutoff of 97%.

In normal rats, inulin treatment did not affect OTU number, the Shannon diversity or the Chao1 index ([Table 1](#table-1){ref-type="table"}). However, in diabetic rats, inulin treatment significantly reduced the Shannon diversity index of the gut microbiota (*P* \< 0.05, [Table 1](#table-1){ref-type="table"}). The richness of the gut microbiota was also significantly reduced by inulin treatment in diabetic rats, as shown by the Chao1 index (*P* \< 0.01, [Table 1](#table-1){ref-type="table"}). To compare the beta diversity of gut microbiota among groups, principal coordinate analysis (PCoA) was carried out. As shown in [Fig. 3](#fig-3){ref-type="fig"}, the first two principal coordinates of PCoA (components 1 and 2) were separated into CON, DM, and DM + inulin groups. However, the CON and CON + inulin groups shared some overlapping regions.

10.7717/peerj.4446/table-1

###### Alpha diversity indices.

![](peerj-06-4446-g009)

            CON            CON + inulin   DM                                                                                      DM + inulin
  --------- -------------- -------------- --------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  OTUs      561.8 ± 27.6   556.8 ± 22.8   499.5 ± 29.9[^\*\*^](#table-1fn){ref-type="fn"}^,^[^\#\#^](#table-1fn){ref-type="fn"}   423.5 ± 48.5[^\*\*^](#table-1fn){ref-type="fn"}^,^[^\#\#^](#table-1fn){ref-type="fn"}^,^[^\$\$^](#table-1fn){ref-type="fn"}
  Chao1     608.3 ± 23.7   588.0 ± 33.1   556.0 ± 32.2[^\*\*^](#table-1fn){ref-type="fn"}                                         467.3 ± 55.5[^\*\*^](#table-1fn){ref-type="fn"}^,^[^\#\#^](#table-1fn){ref-type="fn"}^,^[^\$\$^](#table-1fn){ref-type="fn"}
  Shannon   6.85 ± 0.29    6.77 ± 0.26    6.39 ± 0.34[^\*^](#table-1fn){ref-type="fn"}^,^[^\#^](#table-1fn){ref-type="fn"}        5.93 ± 0.40[^\*\*^](#table-1fn){ref-type="fn"}^,^[^\#\#^](#table-1fn){ref-type="fn"}^,^[^\$^](#table-1fn){ref-type="fn"}

**Notes.**

Data are presented as means ± SD (*n* = 6). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 versus CON, ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus CON +inulin; ^\$^*P* \< 0.05, ^\$\$^*P* \< 0.01 versus DM (one-way ANOVA followed by Tukey's post hoc test).

![PCoA of unweighted Unifrac distances of the gut bacterial communities.\
Pyrosequencing data was analyzed with QIIME and subjected to unweighted Unifrac analysis. Component 1 explains 38.47% of the variation, component 2 explains 8.5% of the variation.](peerj-06-4446-g003){#fig-3}

Relative abundances of different bacteria in the gut microbiota after inulin treatment
--------------------------------------------------------------------------------------

As shown above, the CON and CON + inulin groups had similar alpha and beta diversities in gut microbiota. Next, we explored the similarities and differences of species distribution in the CON, DM, and DM + inulin groups. As shown in [Fig. 4](#fig-4){ref-type="fig"}, we found that there were 602 species shared among the three groups, accounting for approximately three or four of the OTUs in each group. Of note, 88 species were found in the CON group, 31 OTUs in the DM group, and 24 OTUs in the DM + inulin group.

![Shared OUT analysis of the different groups.\
Venn diagram showing the unique and shared OTUs (3% distance level) in the different groups.](peerj-06-4446-g004){#fig-4}

Consistent with other reports, the primary phyla were *Bacteroidetes* and *Firmicutes* in all samples. The DM group had an elevated relative abundance of *Firmicutes* (*P* \< 0.01) and a reduced abundance of *Bacteroidetes* (*P* \< 0.01). Inulin treatment reduced the relative abundance of *Firmicutes* (*P* \< 0.01) and increased the abundance of *Bacteroidetes* (*P* \< 0.01, [Fig. 5A](#fig-5){ref-type="fig"}) in diabetic rats. The ratio of *Firmicutes*-*Bacteroidetes* has been suggested to be an indicator of gut microbial imbalance related to high-fat diet ([@ref-25]; [@ref-40]; [@ref-54]). Our results showed that DM rats had a higher ratio of *Firmicutes*-*Bacteroidetes* (*P* \< 0.01), whereas inulin treatment reuced this ratio (*P* \< 0.01, [Fig. 5B](#fig-5){ref-type="fig"}). Moreover, inulin treatment reduced the relative abundance of *Tenericutes* in diabetic rats (*P* \< 0.05, [Fig. 5A](#fig-5){ref-type="fig"}).

![Fecal microbial communities at the phyla level.\
(A) Relative abundance of gut microbiota at the phyla level, and (B) the ratio of *Bacteroidetes*: *Firmicutes*. Data are presented as means ± SD (*n* = 6). \*\**P* \< 0.01, ^NS^ not significant (one-way ANOVA followed by Tukey's post hoc test).](peerj-06-4446-g005){#fig-5}

According to our LDA of the effective size, the abundances of many taxa were significantly different among the CON, DM, and DM + inulin groups ([Figs. 6](#fig-6){ref-type="fig"} and [7](#fig-7){ref-type="fig"}). At the family level, the *Streptococcaceae* and *Acidaminococcaceae* abundances were elevated in the DM + inulin group compared to the DM group, whereas the *Christensenellaceae*, *Peptococcaceae*, and *Desulfovibrionaceae* abundances were reduced in the DM + inulin group (*P* \< 0.05, [Table 2](#table-2){ref-type="table"}). At the genus level, the *Phascolarctobacterium*, *Streptococcus*, *Lachnoclostridium*, and *Parasutterella* abundances were all significantly elevated by inulin treatment, whereas the *Ruminococcaceae_NK4A214_group*, *Alloprevotella*, *Ruminococcaceae_UCG_010*, *Ruminiclostridium_6*, *Christensenellaceae_R\_7_group*, *Desulfovibrio*, and *Oscillibacter* abundances were reduced by inulin treatment in diabetic rats (*P* \< 0.05, [Table 2](#table-2){ref-type="table"}). At the species level, *Lactobacillus_animalis, Ruminococcus_gnavus, Phascolarctobacterium_faecium, Streptococcus_hyointestinalis,* and *Bacteroides_acidifaciens* were more abundant in the DM + inulin group (*P* \< 0.05, [Table 2](#table-2){ref-type="table"}).

![Cladogram indicating statistical differences of microbial populations in rats.](peerj-06-4446-g006){#fig-6}

![LDA scores indicating statistical differences of microbial populations in rats.](peerj-06-4446-g007){#fig-7}
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###### The relative abundance (%) of bacterial groups that showed statistical significance based on the LEfSe method.

![](peerj-06-4446-g010)

  Bacterial group                        *P*-value   Percentual abundance (%)                                                                                      
  -------------------------------------- ----------- -------------------------- ------------------------ --------------------------------------------------------- --------------------------------------------------------------------------------------------
  *Streptococcaceae*                     3.351       0.013                      0.135(0.013--0.920)      0.042(0.037--0.080)                                       0.227(0.150--2.070)[^\#\#^](#table-2fn){ref-type="fn"}
  *Escherichia_Shigella*                 3.819       0.044                      0.168(0.043--0.313)      0.238(0.060--4.940)                                       1.313(0.160--3.003)[^\*^](#table-2fn){ref-type="fn"}
  *Phascolarctobacterium*                3.146       0.027                      0.000(0.000--0.037)      0.000(0.000--0.017)                                       0.030(0.000--1.027)[^\#^](#table-2fn){ref-type="fn"}
  *Bacteroides*                          4.726       0.006                      3.168(0.880--17.521)     7.917(3.180--14.854)                                      12.584(9.930--28.454)[^\*\*^](#table-2fn){ref-type="fn"}
  *Ruminococcus_1*                       4.032       0.001                      2.422(0.680--4.080)      1.538(0.703--1.860)                                       0.263(0.067--1.103)[^\*\*\*^](#table-2fn){ref-type="fn"}
  *Enterobacteriales*                    3.826       0.016                      0.187(0.043--0.353)      0.273(0.070--5.040)                                       1.357(0.263--3.087)[^\*^](#table-2fn){ref-type="fn"}
  *Bacteroides_ovatus*                   3.619       0.023                      0.062(0.013--0.297)      0.107(0.013--0.190)                                       0.447(0.053--3.743)[^\*^](#table-2fn){ref-type="fn"}
  *Desulfovibrionales*                   4.029       0.013                      1.065(0.517--1.923)      2.433(1.827--5.147)[^\*^](#table-2fn){ref-type="fn"}      0.853(0.557--5.707) [^\#^](#table-2fn){ref-type="fn"}
  *unidentified_Ruminococcaceae*         3.857       0.009                      1.505(0.457--2.087)      2.650(1.677--5.050)[^\*\*^](#table-2fn){ref-type="fn"}    1.663(0.440--4.993)
  *\_Eubacterium\_\_ruminantium_group*   3.205       0.045                      0.082(0.003--2.277)      0.028(0.007--0.087)                                       0.007(0.000--0.220)[^\*^](#table-2fn){ref-type="fn"}
  *Ruminococcaceae_NK4A214_group*        3.673       0.012                      0.957(0.577--2.143)      1.273(0.500--2.513)                                       0.507(0.213--1.000)[^\#^](#table-2fn){ref-type="fn"}
  *Prevotellaceae_UCG_001*               3.812       0.001                      0.950(0.360--3.397)      0.077(0.007--0.153)[^\*\*^](#table-2fn){ref-type="fn"}    0.073(0.010--0.247)[^\*\*^](#table-2fn){ref-type="fn"}
  *Oscillibacter*                        3.914       0.006                      1.042(0.263--1.317)      2.383(1.487--3.187)[^\*^](#table-2fn){ref-type="fn"}      0.617(0.047--2.527)[^\#^](#table-2fn){ref-type="fn"}
  *Streptococcus*                        3.350       0.013                      0.135(0.013--0.913)      0.040(0.037--0.080)                                       0.223(0.150--2.067)[^\#\#^](#table-2fn){ref-type="fn"}
  *Lachnospiraceae_bacterium_COE1*       3.059       0.001                      0.152(0.017--0.697)      0.003(0.000--0.010)[^\*\*^](#table-2fn){ref-type="fn"}    0.003(0.000--0.023)[^\*^](#table-2fn){ref-type="fn"}
  *Christensenellaceae*                  4.152       0.004                      1.585(0.727--2.690)      4.122(2.450--6.210)[^\*^](#table-2fn){ref-type="fn"}      1.280(0.077--2.093)[^\#\#^](#table-2fn){ref-type="fn"}
  *Prevotellaceae_NK3B31_group*          4.047       0.005                      1.382(0.047--7.914)      0.067(0.003--0.113)                                       0.043(0.000--0.097)[^\*\*^](#table-2fn){ref-type="fn"}
  *Lactobacillus_animalis*               4.005       0.016                      1.078(0.267--4.400)      0.212(0.030--0.683)[^\*^](#table-2fn){ref-type="fn"}      0.913(0.413--10.697)[^\#^](#table-2fn){ref-type="fn"}
  *\_Ruminococcus\_\_gnavus*             3.653       0.001                      0.073(0.007--0.213)      0.030(0.003--0.057)                                       0.370(0.180--2.793)[^\*^](#table-2fn){ref-type="fn"}^,^[^\#\#^](#table-2fn){ref-type="fn"}
  *Acidaminococcaceae*                   3.146       0.027                      0.000(0.000--0.037)      0.000(0.000--0.017)                                       0.030(0.000--1.027)[^\#^](#table-2fn){ref-type="fn"}
  *Alphaproteobacteria*                  3.101       0.005                      0.033(0.020--0.080)      0.058(0.030--0.230)                                       0.117(0.083--1.333)[^\*\*^](#table-2fn){ref-type="fn"}
  *Rhodospirillaceae*                    3.092       0.007                      0.033(0.020--0.073)      0.053(0.030--0.230)                                       0.107(0.070--1.333)[^\*\*^](#table-2fn){ref-type="fn"}
  *Betaproteobacteria*                   3.906       0.015                      0.705(0.550--2.027)      1.723(1.293--4.280)                                       1.993(0.863--5.780)[^\*^](#table-2fn){ref-type="fn"}
  *Alloprevotella*                       3.796       0.042                      0.942(0.290--1.370)      1.942(0.160--3.433)                                       0.317(0.040--0.790)
  *Negativicutes*                        3.284       0.005                      0.040(0.000--0.067)      0.013(0.000--0.033)                                       0.330(0.010--1.270)[^\#\#^](#table-2fn){ref-type="fn"}
  *Ruminococcaceae_UCG_013*              3.196       0.002                      0.360(0.033--0.730)      0.090(0.037--0.110)                                       0.020(0.013--0.093)[^\*\*^](#table-2fn){ref-type="fn"}
  *Ruminococcaceae_UCG_010*              3.041       0.001                      0.133(0.097--0.220)      0.317(0.220--0.470)[^\*^](#table-2fn){ref-type="fn"}      0.097(0.030--0.190)[^\#\#^](#table-2fn){ref-type="fn"}
  *Desulfovibrio*                        4.026       0.013                      1.062(0.517--1.913)      2.417(1.797--5.130)[^\*^](#table-2fn){ref-type="fn"}      0.847(0.557--5.667)[^\#^](#table-2fn){ref-type="fn"}
  *Deltaproteobacteria*                  4.029       0.013                      1.065(0.517--1.923)      2.433(1.827--5.147)[^\*^](#table-2fn){ref-type="fn"}      0.853(0.557--5.707)[^\#^](#table-2fn){ref-type="fn"}
  *\_Clostridium\_\_leptum*              3.873       0.007                      1.427(0.427--1.973)      2.610(1.653--4.987)[^\*\*^](#table-2fn){ref-type="fn"}    1.607(0.423--4.903)
  *Gammaproteobacteria*                  3.827       0.018                      0.203(0.043--0.380)      0.292(0.070--5.044)                                       1.357(0.277--3.113)[^\*^](#table-2fn){ref-type="fn"}
  *Lachnospiraceae_UCG_010*              4.023       0.004                      0.335(0.067--0.843)      2.400(1.453--3.640)[^\*\*^](#table-2fn){ref-type="fn"}    1.453(0.050--4.460)
  *Phascolarctobacterium_faecium*        3.146       0.027                      0.000(0.000--0.037)      0.000(0.000--0.017)                                       0.030(0.000--1.027)[^\#^](#table-2fn){ref-type="fn"}
  *Enterobacteriaceae*                   3.826       0.016                      0.187(0.043--0.353)      0.273(0.070--5.040)                                       1.357(0.263--3.087)[^\*^](#table-2fn){ref-type="fn"}
  *Family_XIII*                          3.448       0.036                      0.303(0.173--0.743)      0.903(0.520--1.293)[^\*^](#table-2fn){ref-type="fn"}      0.580(0.110--1.710)
  *Bacteroidales_S24_7\_group*           4.883       0.007                      22.127(16.074--31.254)   7.100(4.260--10.880)[^\*^](#table-2fn){ref-type="fn"}     10.764(1.607--25.278)[^\*^](#table-2fn){ref-type="fn"}
  *Mollicutes*                           3.180       0.040                      0.217(0.060--0.350)      0.375(0.140--0.827)                                       0.103(0.007--0.293)[^\#^](#table-2fn){ref-type="fn"}
  *Lachnoclostridium*                    3.803       0.003                      0.205(0.083--0.333)      0.163(0.047--0.247)                                       0.493(0.237--3.730)[^\*^](#table-2fn){ref-type="fn"}^,^[^\#\#^](#table-2fn){ref-type="fn"}
  *Peptococcaceae*                       3.294       0.044                      0.442(0.173--0.620)      0.673(0.310--1.420)                                       0.323(0.050--0.973)[^\#^](#table-2fn){ref-type="fn"}
  *Parasutterella*                       3.904       0.015                      0.697(0.543--2.013)      1.718(1.293--4.280)                                       1.983(0.853--5.760)[^\*^](#table-2fn){ref-type="fn"}^,^[^\#^](#table-2fn){ref-type="fn"}
  *Prevotellaceae*                       4.319       0.028                      7.814(3.413--12.420)     4.167(0.893--11.080)                                      1.107(0.533--25.004)[^\*^](#table-2fn){ref-type="fn"}
  *Tenericutes*                          3.180       0.040                      0.217(0.060--0.350)      0.375(0.140--0.827)                                       0.103(0.007--0.293)[^\#^](#table-2fn){ref-type="fn"}
  *Ruminiclostridium_6*                  3.869       0.010                      0.387(0.137--0.917)      1.710(0.353--3.273)                                       0.210(0.027--1.687)[^\#\#^](#table-2fn){ref-type="fn"}
  *Ruminiclostridium_5*                  3.101       0.005                      0.598(0.513--0.747)      0.310(0.190--0.517)[^\*^](#table-2fn){ref-type="fn"}      0.407(0.077--0.643)[^\*^](#table-2fn){ref-type="fn"}
  *Streptococcus_hyointestinalis*        3.350       0.015                      0.125(0.010--0.907)      0.028(0.003--0.067)                                       0.207(0.137--2.040)[^\#^](#table-2fn){ref-type="fn"}
  *Christensenellaceae_R\_7_group*       4.142       0.003                      1.455(0.640--2.543)      4.008(2.323--6.034)[^\*^](#table-2fn){ref-type="fn"}      1.203(0.070--2.010)[^\#\#^](#table-2fn){ref-type="fn"}
  *Family_XIII_AD3011_group*             3.075       0.037                      0.092(0.047--0.257)      0.315(0.127--0.633)[^\*^](#table-2fn){ref-type="fn"}      0.190(0.033--0.473)
  *Selenomonadales*                      3.284       0.005                      0.040(0.000--0.067)      0.013(0.000--0.033)                                       0.330(0.010--1.270)[^\#\#^](#table-2fn){ref-type="fn"}
  *Proteobacteria*                       4.370       0.003                      2.180(1.260--3.910)      5.952(3.557--14.327)[^\*\*^](#table-2fn){ref-type="fn"}   5.760(2.603--11.244)[^\*^](#table-2fn){ref-type="fn"}
  *Bacteroidaceae*                       4.726       0.006                      3.168(0.880--17.521)     7.917(3.180--14.854)                                      12.584(9.930--28.454)[^\*\*^](#table-2fn){ref-type="fn"}
  *Lachnospiraceae_ND3007_group*         3.423       0.001                      0.048(0.020--3.950)      0.012(0.000--0.033)[^\*^](#table-2fn){ref-type="fn"}      0.003(0.000--0.013)[^\*\*^](#table-2fn){ref-type="fn"}
  *Thalassospira*                        3.092       0.007                      0.033(0.020--0.073)      0.053(0.030--0.230)                                       0.107(0.070--1.333)[^\*\*^](#table-2fn){ref-type="fn"}
  *Rhodospirillales*                     3.092       0.007                      0.033(0.020--0.073)      0.053(0.030--0.230)                                       0.107(0.070--1.333)[^\*\*^](#table-2fn){ref-type="fn"}
  *Alcaligenaceae*                       3.904       0.015                      0.705(0.550--2.027)      1.723(1.293--4.280)                                       1.993(0.853--5.767)[^\*^](#table-2fn){ref-type="fn"}
  *Lachnospiraceae_UCG_005*              3.961       0.008                      0.757(0.270--1.470)      2.562(1.710--2.987)[^\*^](#table-2fn){ref-type="fn"}      3.050(0.130--4.503)[^\*^](#table-2fn){ref-type="fn"}
  *Desulfovibrionaceae*                  4.029       0.013                      1.065(0.517--1.923)      2.433(1.827--5.147)[^\*^](#table-2fn){ref-type="fn"}      0.853(0.557--5.707)[^\#^](#table-2fn){ref-type="fn"}
  *Escherichia_coli*                     3.817       0.035                      0.160(0.040--0.297)      0.210(0.057--4.927)                                       1.237(0.147--2.987)[^\*^](#table-2fn){ref-type="fn"}
  *Bacteroides_acidifaciens*             4.030       0.002                      0.247(0.103--1.103)      0.125(0.023--0.337)                                       1.610(0.540--6.377)[^\#\#^](#table-2fn){ref-type="fn"}
  *Burkholderiales*                      3.906       0.015                      0.705(0.550--2.027)      1.723(1.293--4.280)                                       1.993(0.863--5.780)[^\*^](#table-2fn){ref-type="fn"}
  *Anaerotruncus*                        3.648       0.005                      0.612(0.400--0.790)      1.618(0.997--1.980)[^\*\*^](#table-2fn){ref-type="fn"}    0.820(0.160--1.633)

**Notes.**

Data are presented as median (minimum-maximum), *n* = 6 in each group. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 versus CON group, ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus DM group (Kruskal--Wallis test and the Mann--Whitney test).

Correlations between metabolic biomarkers and bacterial abundance
-----------------------------------------------------------------

At the genus level, *Prevotellaceae_UCG-001* and *Lachnospiraceae_UCG-006* abundances were negatively correlated with blood glucose AUC on the OGTT (*P* \< 0.01, [Figs. 8A](#fig-8){ref-type="fig"} and [8B](#fig-8){ref-type="fig"}). The *Anaerovorax* abundance showed a positive correlation with blood glucose AUC on the OGTT (*P* \< 0.01, [Fig. 8C](#fig-8){ref-type="fig"}).

![Correlation analysis between relative abundance (%) of gut bacteria and blood glucose response to glucose load.\
(A) *Prevotellaceae_UCG-001*, (B) *Lachnosporaceae_UCG-006*, and (C) *Anaerovorax*. *n* = 6 in each group (Spearman's correlation analysis).](peerj-06-4446-g008){#fig-8}

Discussion
==========

In this study, we employed a combination of high-fat diet and low-dose STZ injections to mimic human T2DM characteristics, including hyperglycemia, hyperinsulinemia, and dyslipidemia. In this protocol, low-dose STZ injections were administered to rats to slightly damage pancreatic β cells. Furthermore, long term feeding of the high-fat diet induced insulin resistance and dyslipidemia. This T2DM animal model has been used by several studies ([@ref-17]; [@ref-52]). Interestingly, we found that inulin treatment effectively moderated glucose intolerance, insulin resistance, and blood lipid panels in the HF/STZ-induced diabetic rat model. A recent meta-analysis showed that inulin-type fructans reduce fasting blood glucose in T2D patients ([@ref-34]). Moreover, in pre-diabetic subjects, inulin moderated insulin resistance in an impaired fasting blood subgroup ([@ref-23]). A combined supplement of inulin and fiberol-2 (another type of soluble dietary fiber) induced in a reduction in blood lipids in hamsters with hyperlipidemia ([@ref-26]). Moreover, inulin treatment increased serum GLP-1 level, reduced serum IL-6 level and *Il6* expression in white adipose tissue of diabetic rats. Previous research indicated that GLP-1 agonist (exendin-4) could inhibit the secretion of IL-6 ([@ref-24]). GLP-1 inhibit macrophage inflammation both in the human cell and the animal model ([@ref-7]; [@ref-31]). IL-6 has been proven to have effects in various tissues including liver ([@ref-1]; [@ref-3]; [@ref-44]). It is reported that the injection of recombinant IL-6 in rats resulted the increase of hepatic *Il6* and *Pepck* expression ([@ref-3]). In our research, HF/STZ-induced diabetic rats had increased expression of hepatic gluconeogenesis. Inulin treatment suppressed hepatic *Pepck* and *G6pc* expression. Thus, enhanced serum GLP-1 levels induced by inulin may be correlated with the reduction of IL-6 production and secretion and the suppression of hepatic gluconeogenesis, resulting in the moderation of insulin resistance in diabetic rats.

According to an alpha diversity analysis, we found that bacterial diversity and richness significantly decreased in the DM + inulin group compared to that in the DM group. An analysis of unweighted UniFrac confirmed the distinct clustering of the relative abundances of OTUs among CON, DM, and DM + inulin rats. However, in normal rats, inulin did not influent alpha and beta diversity of the gut microbiota. Therefore, inulin administration may reduce the whole microbiota diversity and shape the specific structure of the gut microbiota only in diabetic rats, not in normal rats.

Our data showed that the *Firmicutes*: *Bacteroidetes* ratio was increased in DM rat fecal microbiota. Inulin treatment reduced this ratio. Previous studies reported that there was a positive correlation between the *Firmicutes*: *Bacteroidetes* ratio and both obesity and diabetes ([@ref-32]; [@ref-33]). Dietary porphyrin (a water soluble fiber) prevented hyperglycemia and substantially enhanced *Bacteroides* abundance in the cecum of KKAy diabetic mice ([@ref-28]).

Moreover, we found that inulin treatment increased *Lactobacillus* abundance in gut microbiota. As a major probiotic, *Lactobacillus* are considered to be key bacteria, that benefit the health of the intestinal tract ([@ref-41]). *Lactobacillus* produces lactic acid, CO~2~, acetic acid, and/or ethanol, which contribute to a more acidic environment through homo- or heterofermentative metabolism ([@ref-37]). Previous studies found that *Lactobacillus* decreased in diabetic rats ([@ref-61]) and HF rats ([@ref-30]). Inclusion of feruloylated oligosaccharides from maize bran in the normal diet of rats increased *Lactobacillus* in fecal microbiota ([@ref-42]). Whole wheat consumption was associated with a three-fold higher abundance of *Lactobacillus* compared to both obese and lean control mice ([@ref-22]). Inulin treatment selectively stimulated beneficial Lactobacilli *in vitro* ([@ref-50]; [@ref-55]) and in human subjects and rodents ([@ref-9]; [@ref-48]; [@ref-58]).

In addition, we found that at the genus level, inulin treatment increased the abundances of *Bacteroides, Phascolarctobacterium*, and *Lachnoclostridium*. *Lachnospiraceae* abundance was negatively correlated with AUC on the OGTT. *Bacteroides*, *Phascolarctobacterium*, and *Lachnospiraceae* are SCFA-producing bacteria. SCFAs have been recently demonstrated to be key regulators of host metabolism and immunity. SCFAs are produced by the gut microbiome. The main components of SCFAs are acetates, propionates and butyrates and are produced through anaerobic fermentation of carbohydrates from indigestible dietary fiber ([@ref-43]). SCFAs are absorbed and utilized by colonocytes and peripheral tissue for energy or act as substrates for lipogenesis, gluconeogenesis or regulation of cholesterol synthesis in the liver. Knockdown of SCFA receptors leads to inflammation, glucose intolerance and diet-induced obesity in mice ([@ref-6]). Butyrate supplementation prevented insulin resistance and obesity in mice ([@ref-21]). Recently, a randomized double-blind, placebo-controlled trial indicated that butyrate and insulin supplementation significantly reduced fasting blood glucose and waist to hip ratio in T2DM patients ([@ref-49]). Previous studies showed that the abundance of *Bacteroides* in T2DM Chinese patients was only half that of normal glucose tolerance subjects and prediabetics ([@ref-64]). [@ref-59] also found that *Bacteroide vulgatus* was less represented in the microbiota of a diabetic group than in the microbiota of a non-diabetic group. Both berberine and metformin increased *Bacteroides* abundance in HF diet-induced obese rats ([@ref-65]). Physically fit healthy subjects showed increased abundances of *Lachnospiraceae* in fecal microbiota and increased production of fecal butyrate. *Lachnospiraceae* abundance exhibited positive correlations with peak oxygen uptake, the gold standard measure of cardiorespiratory fitness ([@ref-20]). Both berberine and metformin treatment markedly increased the abundance of *Phascolarctobacterium* in gut microbiota ([@ref-65]).

Our data also showed that *Desulfovibrio* abundance was lower in inulin-treated rats than in DM rats. As Gram-negative bacteria, most members of *Desulfovibrio* are lipopolysaccharide (LPS) producers ([@ref-35]; [@ref-57]) and damage the gut barrier ([@ref-5]). HFD can induce a leaky gut and cause bacterial lysis, allowing the LPS of Gram-negative bacteria to enter the enterohepatic circulation ([@ref-16]). LPS can activate pro-inflammatory cytokine production, leading to impaired insulin sensitivity and induction of insulin resistance-related metabolic disorders ([@ref-10]). Our results also showed that inulin treatment reduced serum IL-6 levels and adipose tissue *Il6* expression in diabetic rats. Previous studies found that the family *Desulfovibrionaceae* caused extensive impaired glucose tolerance (IGT)/obese rats ([@ref-62]). Consumption of the Western diet (high fat, high sugar) for one month led to increased LPS in healthy individuals ([@ref-45]). [@ref-60] found that *Desulfovibrio* abundance was markedly increased in STZ-HFD induced nonalcoholic steatohepatitis and was positively correlated with LPS levels.

*Ruminococcaceae* abundance was lower in inulin-treated rats than in non-treated diabetic rats. In another study, there was a reduction in the abundance of *Ruminococcaceae* in bitter melon formulation-treated rats (which reduced fasting blood glucose) compared to diabetic rats ([@ref-66]). *Oscillibacter* is one species within the *Ruminococcaceae* family whose abundance is positively correlated with gut permeability, which can affect gut barrier integrity ([@ref-29]). The abundance of *Oscillibacter* increased under HFD conditions, and the abundance of *Oscillibacter* declined after inhibition of the mTOR complex ([@ref-27]).

Conclusion
==========

In summary, our study supports the hypothesis that inulin-induced changes to the composition of the gut microbiota in diabetic rats are linked to the anti-diabetic effects of inulin. In particular, inulin treatment enhanced the abundance of beneficial bacteria, including SCFA-producing bacteria and probiotic bacteria, and reduced the abundance of LPS-producing bacteria in the gut. Moreover, inulin treatment enhanced serum GLP-1 level to suppress IL-6 secretion and production and hepatic gluconeogenesis, and resulted in moderation of insulin tolerance. These findings indicate that gut-liver crosstalk is the main mechanism in moderation of insulin resistance by inulin. Our study provides evidence that the gut microbiota may be a relevant diabetes treatment. More studies are needed to investigate whether or not inulin treatment can directly moderate gut microbiota and glucose metabolism.

Supplemental Information
========================

10.7717/peerj.4446/supp-1

###### Raw data

###### 

Click here for additional data file.

We are very grateful to Beijing Compass Biotechnology Company for excellent technical assistance with 16s sequencing experiments.

Additional Information and Declarations
=======================================

Dr. Xiaobing Yu is an employee of Fengning Ping'an High-tech Industrial Co., Ltd.

[Qian Zhang](#author-1){ref-type="contrib"} conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

[Hongyue Yu](#author-2){ref-type="contrib"} performed the experiments, authored or reviewed drafts of the paper, approved the final draft.

[Xinhua Xiao](#author-3){ref-type="contrib"} conceived and designed the experiments, authored or reviewed drafts of the paper, approved the final draft.

[Ling Hu](#author-4){ref-type="contrib"}, [Fengjiao Xin](#author-5){ref-type="contrib"} and [Xiaobing Yu](#author-6){ref-type="contrib"} analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

All procedures were undertaken with the approval of the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 Feb 2015), and all efforts were made to minimize suffering.

The following information was supplied regarding data availability:

The raw data is provided in [Data S1](#supp-1){ref-type="supplementary-material"}.
